课题基金 / 基金详情

Synthesis of Bioactive Natural Products

Synthesis of Bioactive Natural Products
生物活性天然产物的合成
批准号:
8008963
负责人:
Amos B Smith
金额:
$9.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-01-29 至 2010-11-30

项目摘要

项目成果

Amos B Smith的其他基金

相似基金

相关文献

中文摘要
翻译
自2005年7月以来的24-27年更新的主要目标现在将包括:(A)发展 高效杀虫剂()-根瘤孢酸A的对映选择性全合成,(B)完成 具有挑战性的大环内酯类抗生素()--山梨素A的全合成;以及(C)开发一种可行的 结构复杂的海洋抗肿瘤大环内酯螺内酯A的对映选择性全合成。 与过去一样,这些目标中的每一个都将需要开发尚未预见的新的合成材料 克服无法预见的障碍的方法。这确实是塔吉特的兴奋和沮丧。 定向全合成。 在新的合成方法方面,我们将:(D)开发新的模块化吲哚合成 包括顺序Stille和Buchwald-Hartwig交叉耦合联盟/环化策略,设计于 (E)扩大和展示新的概念: 阴离子接力化学(ARC),这是我们上次更新时引入的一种强大的合成策略 申请,尽管没有“概念证明”。对于后者,我们将探索各种不同的 亲核试剂,具有各种阴离子稳定基团(ASG)的硅基连接钉,以及亲电体 展示各种立体化学复合氧和氮的可行性和快速组装 单个烧瓶中的替代产品。 除了这些具体的综合目标外,该计划的一个总体、长期目标是 鉴定负责生物活性的分子结构。因此,当我们开发一种 对于每个目标,我们还将准备模型化合物,以允许澄清 结构-活性关系。我们在Discodermolide方面的经验给了我们在这方面的极大信心。
英文摘要
The principal goals for the 24-27 years update since July 2005 will now include: (A) development of an enantioselective total synthesis of the potent insecticidal agent (+)-nodulisporic acid A, (B) completion of the total synthesis of the challenging macrolide antibiotic (+)-sorangicin A; and (C) development of a viable enantioselective total synthesis of the architecturally complex marine antitumor macrolide spirastrellolide A. As in the past, each of these targets will require the development of as yet unforeseen new synthetic methodology to overcome unforeseen obstacles. This is indeed the excitement and frustration of target oriented total synthesis. In the area of new synthetic methods, we will: (D) develop the new modular indole synthesis comprising a sequential Stille and Buchwald-Hartwig cross-coupling union/cyclization tactic, devised in conjunction with the nodulisporic acid A synthetic venture; (E) expand and showcase the new concept of Anion Relay Chemistry (ARC), a powerful synthetic tactic introduced at the time of our previous renewal application, albeit without "proof of concept". Towards the latter end,we will explore a wide variety of nucleophiles, silyl linchpins possessing various anion stabilizing groups (ASG), and electrophiles to demonstrate the feasibility and rapid assembly of diverse, stereochemically complex oxygen and nitrogen substituted products in a single flask. Beyond these specific synthetic objectives, a general, long-range goal of this program is the identification of the molecular architecture responsible for biological activity. Thus, as we develop an approach to each target, we will also prepare model compounds designed to permit the elucidation of structure-activity relationships. Our experience with discodermolide gives us great confidence in this area.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dictyostatin and related prodrugs as candidates for tauopathy treatment
  • 批准号:
    8821175
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2014
  • 负责人:
    Amos B Smith
  • 依托单位:
Alzhelmer's Disease Drug Development Program
  • 批准号:
    7676129
  • 项目类别:
  • 资助金额:
    $64.07万
  • 财政年份:
    2008
  • 负责人:
    Amos B Smith
  • 依托单位:
Alzhelmer's Disease Drug Development Program
  • 批准号:
    7525036
  • 项目类别:
  • 资助金额:
    $63.32万
  • 财政年份:
    2008
  • 负责人:
    Amos B Smith
  • 依托单位:
Alzhelmer's Disease Drug Development Program
  • 批准号:
    8118501
  • 项目类别:
  • 资助金额:
    $60.96万
  • 财政年份:
    2008
  • 负责人:
    Amos B Smith
  • 依托单位:
海外基金